Tags : Over $200M

Takeda to Divest its Portfolio of Select OTC and Non-Core

Vartika Singh October 15, 2019

Shots: Takeda to receive ~$200M for divesting its 30 select prescription pharmaceutical and OTC products traded in Near East, Middle East and Africa (NEMEA) countries. Acino to get rights, title, […]readmore

Tags : Over $200M

Takeda to Divest its Portfolio of Select OTC and Non-Core

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Over $200M

﻿Takeda to Divest its Portfolio of Select OTC and Non-Core

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Takeda to Divest its Portfolio of Select OTC and Non-Core